Director, Silicon Flatirons Centers' Entrepreneurship Initiative
Chairman, CEO, & Founder, Alexandria Real Estate Equities
CEO of Dynamis Corporation
Managing Director of Hatteras Discovery and Venture Partner at Hatteras Venture Partners
Is conventional equity funding for innovation in the life sciences industry truly a viable strategy for private equity and venture capital firms, or is it all just a house of cards? Against a backdrop that includes some local criticism of Big Pharma’s hardball buyout tactics, the San Diego Venture Group has organized a debate on the merits of the venture-backed biotech business model. Making the case for venture biotech innovation are Wende Hutton of Canaan Partners and Camille Samuels of Versant Ventures; Arguing for a change are Bob More of Frazier Healthcare and Kevin Kinsella of Avalon Ventures. More information and online registration is available here.